Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
376 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Prevalence and Incidence of Hereditary Angioedema: A Systematic Literature Review.
Craig TJ, Riedl MA, Smith TD, Kasireddy E, Lam OLT, McClain MR. · Int Arch Allergy Immunol · 2026 · cited 1 timesOpen accesssystematic review, review-article
- Lonvoguran Ziclumeran - In Vivo CRISPR Gene Editing in Hereditary Angioedema.
Cohn DM, Gurugama P, Longhurst HJ, Aygören-Pürsün E, Craig TJ, Farkas H, Jacobs J, Lumry WR, Magerl M, Peter J, Riedl MA, Maag D, Golden A, Shah MY, Sutherland A, Miller CR, Abdelhady AM, Xu Y, Butler JS, Lebwohl D, Leonard J, Banerji A, HAELO Investigators. · N Engl J Med · 2026 · cited 7 timesclinical trial, phase iii, multicenter study
- Icatibant for acute hereditary angioedema attacks in pediatric patients: A systematized review.
Schmalzried S, Beckett RD, Davis H, Carreon G. · Allergy Asthma Proc · 2026 · cited 1 timessystematic review
- Garadacimab in Hereditary Angioedema: Modeling Suggests Sustained Improvements in Attack-Free Probability and Quality of Life Over 5 Years.
Li PH, Hsu FI, Aygören-Pürsün E, Lumry WR, Raasch J, Pragst I, Li Y, Nenci C, Campioni M, Magerl M. · Clin Transl Sci · 2026 · cited 0 timesOpen accessclinical trial, phase iii
- Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial.
Riedl MA, Li PH, Adatia A, Cancian M, Stobiecki M, Valerieva A, Grumach AS, Lumry WR, Soteres DF, Brodszki N, Fili NL, Hakl R, Kang HR, Karakaya G, Kränke B, Li HH, Peter J, Recke A, Tachdjian R, Triggianese P, Zanichelli A, Anderson J, Aygören-Pürsün E, Craig TJ, Farkas H, Giardino F, Giavina-Bianchi P, Kim S, Kinaciyan T, Martinez-Saguer I, Perego F, Sitz KV, Staevska M, Wedner HJ, Zaragoza-Urdaz RH, Zwiener RD, Gelincik A, Arcoleo F, Arnaout R, Baptist AP, de Albuquerque Campos R, Dorr AD, Ferriani MPL, Fukunaga A, Gobert D, Gurugama P, Hide M, Hong DI, Inage E, Jacobs JS, Katelaris CH, Leeman L, Lleonart R, Magerl M, Manning ME, Mano S, Ooka S, Ramos CJ, Liu J, Zhu L, Mendivil J, Katbeh U, Giannattasio G, Crabbé R, Yu M, Lesage A, Lu P, Cohn DM. · Lancet · 2026 · cited 1 timesclinical trial, phase iii, multicenter study
- Impact of Oral Sebetralstat on Anxiety Associated With Hereditary Angioedema Attacks.
Craig T, Aygören-Pürsün E, Bernstein JA, Busse PJ, Caballero T, Cohn DM, Guilarte M, Farkas H, Jones DH, Kiani-Alikhan S, Manning ME, Maurer M, Riedl MA, Savic S, Wedner HJ, Yong PFK, Zanichelli A, van Kooten S, Iverson M, Hansen E, Hao J, Smith MD, Yea CM, Audhya PK, Lumry WR. · Clin Exp Allergy · 2026 · cited 1 timesOpen accessclinical trial, phase iii, randomized controlled trial
- Exposure-Response Analysis of Donidalorsen for the Treatment of Hereditary Angioedema.
Singh P, Witjes H, Kleijn HJ, Diep JK, Bordone L, Newman KB, Gao X, Cohn DM. · Clin Transl Sci · 2025 · cited 3 timesOpen accessclinical trial, phase iii, research support, non-u.s. gov't
- Berotralstat and Health-Related Quality of Life in Hereditary Angioedema: Pooled Analysis of the APeX-2 and APeX-J Trials.
Caballero T, Kiani-Alikhan S, Johnston DT, Wang A, Lopez-Gonzalez L, Zhou ZY, Yang F, Kim HH, Nestler-Parr S, Tomita D, Gillard P, Kinaciyan T. · Clin Exp Allergy · 2026 · cited 0 timesOpen accessclinical trial, phase iii, randomized controlled trial
- Diverse Trial Designs, Populations, and Outcomes: A Systematic Literature Review of Trials for the Treatment of Hereditary Angioedema Attacks.
Tachdjian R, Narsipur N, Saharia P, Jindal S, Park N, Harper JR, Relan A, Anderson J, Harrington A. · Adv Ther · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Cardiac and vascular autonomic control in patients with hereditary angioedema.
De Maria B, Ranucci L, Gino C, Zulueta A, Parati M, Cesoni Marcelli A, Zingale LC, Sideri R, Dalla Vecchia LA, Perego F. · Front Physiol · 2025 · cited 1 timesOpen accessclinical trial
- Post Hoc Analysis of Recombinant C1 Inhibitor Clinical Data Using Contemporary Endpoints for Hereditary Angioedema.
Riedl MA, Narsipur N, Jones D, Tachdjian R, Relan A, Kilvert H, Aiello E, Habimana K, Roskell N, Gough A, Harper JR, Li HH, Harrington A. · Adv Ther · 2026 · cited 0 timesOpen accessrandomized controlled trial
- Lanadelumab safety, efficacy, and pharmacokinetics in patients aged ≥12 with hereditary angioedema in China: an open-label, multicenter study.
Zhi Y, Zhu R, Sun Y, Lai H, Ren H, Wang Y, Dong L. · Front Immunol · 2026 · cited 0 timesOpen accessclinical trial, phase iii, multicenter study
- Population Pharmacokinetic/Pharmacodynamic Modeling of Donidalorsen, an Antisense Oligonucleotide in Development for Prophylaxis of Hereditary Angioedema.
Diep JK, Liu M, Singh P, Dorow S, Cohn DM, Bordone L, Newman KB, Gao X. · CPT Pharmacometrics Syst Pharmacol · 2026 · cited 2 timesOpen accessresearch support, non-u.s. gov't, clinical trial, phase i
- Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Maurer M, Stobiecki M, Valerieva A, Hakl R, Staevska MT, Bouillet L, Du-Thanh A, Kessel A, Kiani-Alikhan S, Magerl M, Reshef A, Baeza ML, Fain O, Farkas H, Greve J, Guilarte M, Jacobs JS, Li HH, Lleonart R, Manning ME, Sussman GL, Anderson J, Chapdelaine H, Cohn DM, Hagin D, Králíčková P, Ritchie B, Spadaro G, Staubach P, Tarzi MD, Yang WH, Jouvin MH, Crabbé R, van Leeuwen S, Chen H, Zhu L, Knolle J, Lesage A, Lu P, Riedl MA, Aygören-Pürsün E. · Lancet Haematol · 2026 · cited 5 timesclinical trial, phase ii, multicenter study
- Comparative Efficacy of Recombinant C1 Inhibitor Versus Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks: A Matching-Adjusted Indirect Treatment Comparison.
Anderson J, Narsipur N, Jones D, Smith A, Relan A, Aiello E, Roskell N, Gough A, Jindal S, Habimana K, Kilvert H, Li HH, Harrington A. · Adv Ther · 2026 · cited 0 timesOpen accesscomparative study, randomized controlled trial
- Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema.
Banerji A, Craig T, Sitz K, Li HH, Lumry W, Adatia A, Yang W, Jacobs JS, Tachdjian R, Soong W, Manning M, Wedner J, Savic S, Manson A, Valerieva A, Gunsior M, Mugundu G, Cohen T, Bernard K, VanEenwyk C, Joseph K, Best JM, Morabito C, Riedl MA. · J Allergy Clin Immunol · 2026 · cited 1 timesclinical trial, phase ii, research support, non-u.s. gov't
- Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial.
Aygören-Pürsün E, Stobiecki M, Valerieva A, Cancian M, Gompels M, Grigoriadou S, Kiani-Alikhan S, Kinaciyan T, Yang WH, Anderson J, Arcoleo F, Chapdelaine H, Conlon N, Eren E, Guarino MD, Gurugama P, Magerl M, Manning ME, Tarzi MD, Wedner HJ, Zanichelli A, Crabbé R, Mulders S, Levy J, Zhu L, Knolle J, Lesage A, Lu P, Riedl MA. · Lancet Haematol · 2026 · cited 4 timesclinical trial, phase ii, multicenter study
- Donidalorsen for hereditary angioedema: Long-term results from a 4-year, phase 2, open-label extension study.
Manning ME, de Lange M, Bernstein JA, Craig T, Lumry WR, Raasch J, Tachdjian R, Bordone L, Deng Y, Newman KB, Cohn DM. · Ann Allergy Asthma Immunol · 2026 · cited 1 timesclinical trial, phase ii, multicenter study
- Garadacimab in hereditary angioedema due to normal C1INH with F12/PLG mutations.
Cohn DM, Reshef A, Staubach P, Lumry WR, Feuersenger H, Jacobs I, Pragst I, Zuraw B, Bork K. · J Allergy Clin Immunol · 2025 · cited 0 timesclinical trial, phase iii, clinical trial, phase ii
- Donidalorsen for Long-Term Prophylaxis of Hereditary Angioedema Attacks: Results from the OASISplus Open-Label Extension Cohort at Year 1.
Lumry WR, Tachdjian R, Craig T, Karakaya G, Gelincik A, Stobiecki M, Jacobs JS, Gokmen NM, Reshef A, Manning ME, Grammatikos A, Giardino F, Guilarte M, Baptist AP, Bordone L, Newman KB, Treadwell S, Lin T, Yarlas A, Riedl MA, Cohn DM. · J Asthma Allergy · 2026 · cited 3 timesOpen accessclinical trial, case reports
- Donidalorsen Treatment of Hereditary Angioedema in Patients Previously on Long-Term Prophylaxis.
Riedl MA, Bernstein JA, Jacobs JS, Craig T, Banerji A, Perego F, Lumry WR, Wedner HJ, Gierer S, Manning ME, Bordone L, Treadwell S, Lin T, Newman KB, Yarlas A, Cohn DM. · J Allergy Clin Immunol Pract · 2025 · cited 5 timesclinical trial, phase iii, multicenter study
- CRISPR-Based Therapy for Hereditary Angioedema.
Cohn DM, Gurugama P, Magerl M, Katelaris CH, Launay D, Bouillet L, Petersen RS, Lindsay K, Aygören-Pürsün E, Maag D, Butler JS, Shah MY, Golden A, Xu Y, Abdelhady AM, Lebwohl D, Longhurst HJ. · N Engl J Med · 2025 · cited 45 timesclinical trial, phase ii, multicenter study
- Worldwide Prevalence of Hereditary Angioedema: A Systematic Review and Meta-Analysis.
Fisch SA, Rundle AG, Neugut AI, Freedberg DE. · Int Arch Allergy Immunol · 2025 · cited 5 timesmeta-analysis, systematic review
- Patient-Reported Outcomes in the Phase III OASIS-HAE Study of Donidalorsen for Hereditary Angioedema.
Riedl MA, Yarlas A, Bordone L, Treadwell S, Wang S, Newman KB, Cohn DM, Cohn DM. · Allergy · 2025 · cited 9 timesOpen accessclinical trial, phase iii, multicenter study
- Effective long-term prophylaxis with lanadelumab in adolescents with hereditary angioedema: EMPOWER/ENABLE.
Tachdjian R, Banerji A, Busse PJ, Agmon-Levin N, Anderson J, Cancian M, Spadaro G, Enciu C, Estepan DN, Khutoryansky N, Jain S, Recke A. · Pediatr Allergy Immunol · 2025 · cited 11 timesOpen accessmulticenter study, clinical trial, phase iv
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.